Physician profile
Robert D Davis
NPI 1962578187
$700.81
in general payments reported to CMS, 2019-2025
12 companies · $65.75 in 2025
The $65.75 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.63 · 2020: $45.91 · 2021: $108 · 2022: $104 · 2023: $21.43 · 2024: $287 · 2025: $65.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $373.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $171.05 | 2019-2025 | |
| Abbvie INC. | $150.81 | 2022-2024 | |
| Apellis Pharmaceuticals, INC. | $88.41 | 2024 | Syfovre |
| Carl Zeiss Meditec USA, INC. | $84.55 | 2022 | |
| Biotissue Holdings INC. | $74.33 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $22.20 | 2019 | |
| Shire North American Group INC | $21.74 | 2019 | |
| Alcon Vision LLC | $21.43 | 2023 | Total30 |
| Oyster Point Pharma, INC. | $19.64 | 2024 | Ryzumvi, Tyrvaya |
| Allergan, INC. | $17.28 | 2020 | |
| Sun Pharmaceutical Industries INC. | $15.55 | 2020 | |
| Quidel Corporation | $13.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.